Recro Pharma Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Recro Pharma (REPH) Tops Q2 EPS by 72c, Revenues Beat
August 7, 2018 7:09 AM EDTRecro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.62), $0.72 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $21.74 million versus the consensus estimate of $16.66 million.
Our recent efforts have been focused on addressing the Complete Response Letter (CRL) received in May 2018 from... More
